J Davies1, A Gavin, M Band, A Morris, A Struthers. 1. Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, UK. j.i.davies@dundee.ac.uk
Abstract
AIMS: To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics. METHODS:Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase. RESULTS: Compared with placebo, spironolactone reduced systolic BP by 15.6 +/- 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 +/- 0.3 microg l(-1) (P = 0.04, 95% CI 0.02-1.1 microg l(-1)) and PWV by 0.6 +/- 0.2 m s(-1) (P = 0.008, 95% CI 0.18-1.02 m s(-1)). CONCLUSIONS:Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.
RCT Entities:
AIMS: To assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics. METHODS: Ten patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase. RESULTS: Compared with placebo, spironolactone reduced systolic BP by 15.6 +/- 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 +/- 0.3 microg l(-1) (P = 0.04, 95% CI 0.02-1.1 microg l(-1)) and PWV by 0.6 +/- 0.2 m s(-1) (P = 0.008, 95% CI 0.18-1.02 m s(-1)). CONCLUSIONS:Spironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabeticpatients with hypertension.
Authors: Kennedy Cruickshank; Lisa Riste; Simon G Anderson; John S Wright; Graham Dunn; Ray G Gosling Journal: Circulation Date: 2002-10-15 Impact factor: 29.690
Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245
Authors: Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel Journal: Lancet Date: 2002-03-23 Impact factor: 79.321
Authors: Jennifer N Cooper; Ping Tepper; Emma Barinas-Mitchell; Genevieve A Woodard; Kim Sutton-Tyrrell Journal: Clin Exp Hypertens Date: 2011-10-18 Impact factor: 1.749
Authors: Bharathi Upadhya; William G Hundley; Peter H Brubaker; Timothy M Morgan; Kathryn P Stewart; Dalane W Kitzman Journal: J Am Geriatr Soc Date: 2017-05-19 Impact factor: 5.562
Authors: Wolfgang Lieb; Martin G Larson; Emelia J Benjamin; Xiaoyan Yin; Geoffrey H Tofler; Jacob Selhub; Paul F Jacques; Thomas J Wang; Joseph A Vita; Daniel Levy; Ramachandran S Vasan; Gary F Mitchell Journal: Circulation Date: 2008-12-22 Impact factor: 29.690
Authors: John C Murphy; Katherine Morrison; James McLaughlin; Ganesh Manoharan; Aa Jennifer Adgey Journal: J Clin Hypertens (Greenwich) Date: 2011-03-04 Impact factor: 3.738
Authors: Tatjana Kalizki; Bernhard M W Schmidt; Ulrike Raff; Annemarie Reinold; Thomas K Schwarz; Markus P Schneider; Roland E Schmieder; Andreas Schneider Journal: J Clin Hypertens (Greenwich) Date: 2017-02-17 Impact factor: 3.738
Authors: Nathanne S Ferreira; Stêfany B A Cau; Marcondes A B Silva; Carla P Manzato; Fabíola L A C Mestriner; Takayuki Matsumoto; Fernando S Carneiro; Rita C Tostes Journal: Front Pharmacol Date: 2015-03-02 Impact factor: 5.810